Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2A6, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2A6 Proteins (3) and CYP2A6 Kits (1) and many more products for this protein.
Showing 10 out of 108 products:
Human Polyclonal CYP2A6 Primary Antibody for WB - ABIN2801900
Miles, Bickmore, Brook, McLaren, Meehan, Wolf: Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. in Nucleic acids research 1989
Show all 4 references for ABIN2801900
Human Polyclonal CYP2A6 Primary Antibody for ELISA, WB - ABIN1534381
Yamano, Tatsuno, Gonzalez: The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. in Biochemistry 1990
Polymorphisms within the CYP2A6 gene are not a significant cause of high skatole levels.
CYP2A6 gene variants were associated with markedly reduced nicotine and cotinine clearances.
CYP2A6 polymorphisms are associated with poor response to chemotherapy in gastric cancer.
Combined 3D-QSAR and docking procedures yielded precise information about the common and distinct interactions of inhibitors and the enzyme active sites of CYP2A6.
P450 (show CYP2B6 Antibodies) 2A13 is one of the important enzymes that oxidizes polycyclic aromatic hydrocarbons
It was concluded that, although decreased CYP2A6 AS tended to reduce the risk of bladder cancer in Japanese smokers, no significant association was recognized in this population.
Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in young smokers.
Slow nicotine metabolism mediated by CYP2A6 increases risk for tobacco dependence throughout adolescence.
carcinogen exposure and thereby lower risk of lung cancer. Despite the association between nicotine metabolism (CYP2A6 activity phenotype and diplotypes) and smoking intensity
lower lung cancer risk observed in CYP2A6 poor metabolizers is partially explained by the strong influence of CYP2A6 genetic polymorphisms on nicotine uptake and metabolism
phenotypic association studies in population in Nigeria: Data suggest polymorphisms in CYP2A6 exist in the population studied; distribution of CYP2A6 activity is trimodal; influence of age/sex on activity are not significant in this biomarker study.
This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3\; however, it has been renamed CYP2A6.
, cytochrome p450 2A6
, 1,4-cineole 2-exo-monooxygenase
, cytochrome P450 2A6
, cytochrome P450 IIA3
, cytochrome P450(I)
, cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6
, flavoprotein-linked monooxygenase
, xenobiotic monooxygenase